Chronic kidney disease (CKD) affects >850 million people globally and is an important risk factor for cardiovascular disease ...

Propensity score overlap weighting was used to compare outcomes. A composite of incident end-stage kidney disease, sustained 40% estimated glomerular filtration rate (eGFR) decline, or all-cause ...

Therefore, clinicians typically use a formula to check your GFR, which estimates how much blood passes through the glomeruli, tiny units found at the end of the kidneys that filter the blood, each ...

该研究纳入了 2007 年开始接受血液透析并建立了永久性血管通路的成年患者。根据血管通路建立的时间，将患者分为三组：早期建立（血液透析开始前至少 4 个月）、刚好及时建立（血液透析开始前 1 至 3 个月）、晚期建立（血液透析开始后 1 个月内或之后 ...

The kidneys have a few important jobs, but primarily they’re waste-removal experts. Inside your kidneys, blood passes through filtering units called nephrons. The nephrons remove excess nutrients like ...

作为全球首个胰岛素周制剂，依柯胰岛素的疗效和安全性已在ONWARDS系列临床研究中得到证实。EASD2024报道了ONWARDS系列研究的多项事后分析，结果支持依柯胰岛素在不同临床特征T2DM患者中的疗效和安全性一致，且剂量调整依从性好，不增加体能活 ...

The new analysis examined whether semaglutide’s effect on MACE and a combined endpoint of MACE or death from any cause is ...

showing a 24% reduction in the primary composite kidney outcome of time to first kidney failure, persistent ≥ 50% estimated ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular ...

A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney ...

Autosomal dominant polycystic kidney disease (ADPKD) rapid progression appears more likely in patients with visceral adiposity.

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular ...